

Urology Clinical Consults Bladder Cancer Cases From the Community

*Expert Guidance on Translating the Latest Therapeutic Advances
Into Patient Care for Early to Advanced Bladder Cancer*

Saturday, May 14, 2022

**New Orleans Ernest N. Morial Convention Center
Room 278-282 (Second Level)**
900 Convention Center Blvd
New Orleans, LA 70130

5:30-6:00 PM: Registration & Dinner
6:00-7:30 PM: Symposium



Safe & Sound

PVI is adhering to all COVID-19 safety measures as outlined by the conference organizers.

Scan the QR code to register on our website for **Contactless Check-in** and show your check-in screen to bypass the line.

Register online: [PeerView.com/61/Bladder22-Live](https://www.peerview.com/61/Bladder22-Live)



CHAIR & PRESENTER

Ashish M. Kamat, MD, MBBS
The University of Texas
MD Anderson Cancer Center
Houston, Texas



PRESENTER

Matthew D. Galsky, MD
Icahn School of Medicine at Mount Sinai
Tisch Cancer Institute
New York, New York



PRESENTER

Janet Baack Kukreja, MD, MPH, FACS
University of Colorado
Denver, Colorado

Key Reasons to Attend

- Hear expert discussion of the practical aspects of novel therapy options in the context of a urology clinical practice setting and how these approaches can be effectively integrated into patient care through the urologist–oncologist collaborative partnership
- Learn about the emergence of novel bladder-sparing and perioperative approaches for patients with NMIBC and MIBC, strategies to provide appropriate shared decision-making, and opportunities to support clinical trial enrollment
- Understand the role and clinical utility of genetic and molecular testing in advanced bladder cancer and the importance of developing proficiency in employing such testing to inform treatment decisions across multiple lines of therapy

Agenda

5:30 PM: Registration & Dinner

6:00 PM: Symposium

Welcome, Introduction, and Preconsult Prep

Clinical Consult Sessions

- Addressing Unmet Needs in Low- to High-Grade NMIBC With Innovative Therapeutic Solutions: Practice Updates for Urologists
- Reshaping Treatment Algorithms for Nonmetastatic MIBC: Essential Guidance for Urologists on Integrating Novel and Emerging Treatment Approaches Into the Clinic
- Recent Progress and Current Status of Therapy in Advanced/Metastatic Bladder Cancer: What Do Urologists Need to Know?

Symposium Summary, Audience Q&A, and Take-Home Points

7:30 PM: Adjourn

Register Today!

Activity Description

The recent transformation of the bladder cancer therapeutic landscape includes the PD-1/PD-L1–targeting immune checkpoint inhibitors for advanced/metastatic bladder cancer, erdafitinib for *FGFR* mutation–positive bladder tumors, and the antibody–drug conjugates enfortumab vedotin and sacituzumab govitecan in the post–immune checkpoint inhibitor setting. Utilizing these agents in localized disease settings has led to the emergence of novel bladder-sparing and perioperative approaches, including the first regulatory approval of adjuvant immunotherapy in high-risk muscle-invasive bladder cancer. In light of these developments, the challenge for urology professionals is how to best blend the diverse clinical evidence for these agents with the realities of real-world cancer care.

This symposium, developed in collaboration with the Bladder Cancer Advocacy Network, will guide learners through the modern realities of managing bladder cancer across disease and treatment settings. Realistic and diverse patient cases will be directly linked to mini lectures in which bladder cancer experts will interpret clinically meaningful evidence on current and emerging therapeutic options and offer guidance on the clinical integration of these therapies into personalized management plans. Prepare to apply practical lessons stemming from the evidence related to novel systemic therapies, their applications in metastatic bladder cancer, and their emerging uses in locally advanced, resectable, or non–muscle-invasive disease—register today!

Target Audience

This activity has been designed to meet the educational needs of urologists, advanced practice clinicians, oncologists, and other clinicians involved in the management of bladder cancer.

Educational Objectives

Upon completion of this activity, participants should be better able to:

- Implement guideline–concordant genetic and molecular assessment as part of the routine management of patients with bladder cancer while considering the current therapeutic roles and mechanistic rationales of novel systemic therapies across bladder cancer settings and patient populations (eg, localized or metastatic)
- Select patients with early-stage bladder cancer who are eligible for recently approved and emerging therapeutic strategies in the adjuvant and neoadjuvant settings (eg, NMIBC and MIBC) based on recent approvals, clinical evidence, and ongoing trials
- Develop personalized, evidence–based treatment plans for patients with advanced/metastatic bladder cancer that incorporate new agents and combinations (including in the context of a clinical trial), expert recommendations, genetic/molecular status, and principles of shared decision-making and multidisciplinary collaboration
- Employ strategies to facilitate early recognition, reporting, and appropriate management of toxicities associated with newer systemic therapy options for bladder cancer in collaboration with the broader care team, patients, and caregivers



Accreditation, Support, and Credit

In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc., PVI, PeerView Institute for Medical Education, and Bladder Cancer Advocacy Network. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported through independent educational grants from AstraZeneca; Bristol Myers Squibb; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Merck & Co., Inc.

Physician Continuing Medical Education

Medical Learning Institute, Inc. designates this live activity for a maximum of 1.5 *AMA PRA Category 1 Credits*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.